{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "@display": "no"}, "enrolled-dateline": {"#tail": " \n", "#text": "Begun and held at the City of Washington on Friday, the third day of January, two thousand and fourteen"}, "congress": {"#tail": " ", "#text": "One Hundred Thirteenth Congress of the United States of America"}, "#tail": " \n", "#text": "\n", "legis-num": {"#tail": " \n", "#text": "H. R. 4771"}, "official-title": {"#tail": " \n", "@display": "yes", "#text": "To amend the Controlled Substances Act to more effectively regulate anabolic steroids."}, "session": {"#tail": "\n    ", "#text": "At the Second Session"}, "distribution-code": {"#tail": " \n", "@display": "no", "#text": "I"}, "legis-type": {"#tail": " \n", "#text": "AN ACT"}}, "attestation": {"#tail": "\n", "attestation-group": [{"#tail": "\n    ", "#text": "\n      ", "role": {"#tail": "\n    ", "#text": "Speaker of the House of Representatives."}}, {"#tail": "\n  ", "#text": "\n      ", "role": {"#tail": "\n    ", "#text": "Vice President of the United States and President of the Senate."}}], "#text": "\n    "}, "@stage-count": "1", "@bill-stage": "Enrolled-Bill", "@bill-type": "olc", "@dms-id": "H64262D40BC88475CB7B3772A22FF4AC9", "@public-private": "public", "legis-body": {"#tail": " ", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": " \n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Designer Anabolic Steroid Control Act of 2014", "@value": "Designer Anabolic Steroid Control Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H6BBC19EF2A9247C7A4835F15BD4EC227"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": " \n", "#text": "Amendments to the Controlled Substances Act"}, "subsection": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 102(41) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:102/p:41"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 802(41)", "@value": "usc/21/802//41"}, "@parsable-cite": "usc/21/802", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Definitions"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "in subparagraph (A)\u2014"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "HF621985D87834D82980B15437A09B5C6", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "quote": {"#tail": " at the end;", "#text": "and"}, "#text": "in clause (xlix), by striking "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "HDBE262A981D04199B8DF49E9C0C28238", "#text": "\n            "}, {"#tail": " \n", "text": {"#tail": "\n          ", "#text": "by redesignating clause (xlx) as clause (lxxv); and"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HA696E11445004CEFB53FB1661641AB1C", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "#text": "by inserting after clause (xlix) the following:"}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "clause": [{"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "5\u03b1-Androstan-3,6,17-trione;"}, "enum": {"#tail": "\n                ", "#text": "(l)"}, "#text": "\n                ", "@id": "HA65CF299E6D446DB99E085D676814B41"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6-bromo-androstan-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(li)"}, "#text": "\n                ", "@id": "H63DEF77CBB19452C8059407CC7CB3EF7"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6-bromo-androsta-1,4-diene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lii)"}, "#text": "\n                ", "@id": "H8F74B99F819A4F579A89E5F177CE815E"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liii)"}, "#text": "\n                ", "@id": "H840B97B7DC8C4729A633DC34A28AFD64"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androst-4-ene-3\u03b2,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liv)"}, "#text": "\n                ", "@id": "H4FA45A6E6A6E420C9052FA0EFCE2C5B7"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-en-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lv)"}, "#text": "\n                ", "@id": "HC485FD56BE00497B84E1F4EF0D346E87"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-ene-3,11-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lvi)"}, "#text": "\n                ", "@id": "H79C3243391D041D18AB99261A136D199"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lvii)"}, "#text": "\n                ", "@id": "HFEDB448698F54BBD883BA75C9F363C9F"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b1-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lviii)"}, "#text": "\n                ", "@id": "H158C4698A69141A6BEDC642A4D6365CF"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b2-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lix)"}, "#text": "\n                ", "@id": "H78EA4DC064444AB587D8CD6789030070"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,3\u03b1-epithio-17\u03b1-methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lx)"}, "#text": "\n                ", "@id": "HABC395D1EB0942D79157BF72E3E749DC"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "[3,2-c]-furazan-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxi)"}, "#text": "\n                ", "@id": "H834EBAC752D5456EA610F1661ADF97DB"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "3\u03b2-hydroxy-estra-4,9,11-trien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxii)"}, "#text": "\n                ", "@id": "HE41FF1FAA8C246D38B1538C0C181E77B"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androst-2-ene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiii)"}, "#text": "\n                ", "@id": "HDC9F6A8CB95F44688CD5F1B703272D14"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiv)"}, "#text": "\n                ", "@id": "HC5AA50EE227C47DD9AC33666872D1D00"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "Estra-4,9,11-triene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxv)"}, "#text": "\n                ", "@id": "H35261204EB494160934E343E59B9FD89"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxvi)"}, "#text": "\n                ", "@id": "HD907DC2C397A455CB745946FF7D9BBE7"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6\u03b1-Methyl-androst-4-ene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxvii)"}, "#text": "\n                ", "@id": "HFA6793B9072B445A98A2D0B298025E1D"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-androstan-3-hydroxyimine-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxviii)"}, "#text": "\n                ", "@id": "H883345755481417BAE398DCB57D4D560"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxix)"}, "#text": "\n                ", "@id": "H1F19D00C0977400181EB7547E5EBE945"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[2,3-d]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxx)"}, "#text": "\n                ", "@id": "H0F6B607B868C4BA5BE90384F9CE02945"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[3,2-c]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxxi)"}, "#text": "\n                ", "@id": "H4391CD6574FF4073B9CD569B74F25AD3"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxii)"}, "#text": "\n                ", "@id": "H0D64D70C134C40548708D01C0DB1DC53"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-androst-4-en-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxiii)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "HAAE6CB2766984FCDAD408C51D4D3892F", "@commented": "no"}, {"@indent": "paragraph", "#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol; and"}, "enum": {"#tail": "\n                ", "#text": "(lxxiv)"}, "#text": "\n                ", "@id": "HF7C6710578FB4326B804C6D1BA74F953"}], "@display-inline": "no-display-inline", "#text": " \n", "@id": "H60710B497A3545DBABA44BB818894796"}, "#text": "\n            ", "@id": "H0BBA73395CE74F5A9078AA4E964DBF58"}]}, {"#tail": "\n      ", "text": {"#tail": " \n", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "@id": "H80846B660E8F46D59ECFB2FA4845675A", "@display-inline": "no-display-inline", "#text": " \n", "subparagraph": {"@indent": "up2", "#tail": "\n            ", "clause": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "Subject to clause (ii), a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in subparagraph (A) and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in subparagraph (A) shall be considered to be an anabolic steroid for purposes of this Act if\u2014"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "subclause": [{"@indent": "up1", "#tail": " \n", "text": {"#tail": " \n", "#text": "the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"#tail": " \n", "text": {"#tail": "\n                  ", "#text": "promotes muscle growth; or"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "@id": "HEAAF26BC71444905AFA5232C2DDEB7DB", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "otherwise causes a pharmacological effect similar to that of testosterone; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "@id": "H5326B07A8FB2482B8249FA932C048324", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H44D0D1DFDB314DCABEF9B1DADA9B826C"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone."}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "#text": "\n                  ", "@id": "HDFB1400279B147E89CA0E5DAB7B35487"}], "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "HC212D296FC2C40CDA20A81C11848CE33", "@commented": "no"}, {"@indent": "up1", "#tail": " \n", "text": {"#tail": " \n", "#text": "A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it\u2014"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "subclause": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "is\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"#tail": " \n", "text": {"#tail": "\n                  ", "#text": "an herb or other botanical;"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "@id": "H9DF0392FF9814FB99F9ACD7D1DDEF429", "#text": "\n                    "}, {"#tail": " \n", "text": {"#tail": "\n                  ", "#text": "a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "@id": "H9CC4328BD67F4170BB96960309AB4B3E", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "a combination of 2 or more substances described in item (aa) or (bb);"}, "enum": {"#tail": "\n                    ", "#text": "(cc)"}, "@id": "HAEBCFDA8B8CB466F84F22A263EFE4361", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H079BFEA4DD724EE2985EE58042F9992B"}, {"#tail": " \n", "text": {"#tail": "\n                ", "#text": "is a dietary ingredient for purposes of the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "@entity-type": "law-citation", "#text": "\n                      ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}, "@parsable-cite": "usc/21/301", "#text": "\n                      ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "HD78B9A612C974CE2B643B3BC79B97AA3", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "is not anabolic or androgenic.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(III)"}, "@id": "H26EFE23E9AB44686B6592192F0C324E2", "#text": "\n                  "}], "#text": "\n                ", "@id": "HB5B8C6BC6E6745BF89D378C64C8145E3"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", any person claiming the benefit of an exemption or exception under clause (ii) shall bear the burden of going forward with the evidence with respect to such exemption or exception.", "@entity-type": "act", "#text": "section 515(a)", "@value": "Controlled Substances Act/s:515/ss:a"}, "#text": "In accordance with "}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "#text": "\n                ", "@id": "H2E017488564A40CEBA5C3FCF1375A5CD"}], "enum": {"#tail": " \n", "#text": "(C)"}, "#text": "\n              ", "@id": "H30EFDA08DDE042E8A61AFEFA362CA9CB"}}, "#text": "\n          ", "@id": "H240EB239767A4DEE85EC636F46AA7814"}], "#text": "\n        ", "@id": "H4219060668CF43299B524BB005DA3D72"}, {"#tail": "\n    ", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 811", "@value": "usc/21/811"}, "@parsable-cite": "usc/21/811", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Classification authority"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(i)"}, "header": {"#tail": " \n", "#text": "Temporary and permanent scheduling of recently emerged anabolic steroids"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " finds that\u2014", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "#text": "\n              ", "@id": "HA5F2D61FAA3046E08F4354F4CED05B4F", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " but is not listed in that section or by regulation of the ", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/p:41"}, {"#tail": " as being an anabolic steroid; and", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "the drug or other substance satisfies the criteria for being considered an anabolic steroid under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HB9EAF651D20F4873888EE5F41298CA89", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H3A78B56B2EBC4E37A4449A34289291A4", "#text": "\n                "}]}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may, during the pendency of proceedings under paragraph (6), extend the temporary scheduling order for up to 6 months.", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "An order issued under paragraph (1) shall not take effect until 30 days after the date of the publication by the "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "H93C402EEE407475CAB1D9261DF0EC195", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall transmit notice of an order proposed to be issued under paragraph (1) to the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ". In issuing an order under paragraph (1), the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "@id": "H8CE27C3CD9F649A09C8BA7EC326CE2C4", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "#text": "A temporary scheduling order issued under paragraph (1) shall be vacated upon the issuance of a permanent scheduling order under paragraph (6)."}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "@id": "H4696AD894103424D8DCBEBBF025D552B", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "#text": "An order issued under paragraph (1) is not subject to judicial review."}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "@id": "HA711F6AFAB86402B930E94F6C5B0351A", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ". Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under paragraph (1).", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/p:41"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "@id": "H4AE7A22957D84DC7A8175C022B3D0B84", "#text": "\n              "}], "#text": "\n            ", "@id": "H9E7A41E785B44410854797DB2734FCBF"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "H21723D86BAAA4F49BB28391D3E743AE8"}, "#text": "\n        ", "@id": "H1D152C684A694BC7A9FBBCD256B56A96"}], "#text": "\n      ", "@id": "HEB87C1E8A1964E699FDB217DE0FB01D7"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": " \n", "#text": "Labeling requirements"}, "subsection": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 305 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:305"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 825", "@value": "usc/21/825"}, "@parsable-cite": "usc/21/825", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": " \n", "#text": "False Labeling of Anabolic Steroids"}, "paragraph": [{"#tail": " \n", "text": {"#tail": "\n            ", "#text": "It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "HAD4C7D05540A4162886EF6622B3CE0F2", "#text": "\n              "}, {"#tail": "\n          ", "@id": "H9CB90F0B8AD042088328EC737BE9A8C1", "enum": {"#tail": " \n", "#text": "(2)"}, "#text": "\n              ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "#text": "A product described in subparagraph (B) is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "H774C3E7B83224673975DC3E064B7AC48", "@commented": "no"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": " \n", "#text": "A product is described in this subparagraph if the product\u2014"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "clause": [{"#tail": " \n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": "; or", "@entity-type": "act", "#text": "(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}], "#text": "is the subject of an approved application as described in "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "#text": "\n                  ", "@id": "H971F59DC427143ED96FB5EFA14EF52F0", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": " \n", "#text": "is exempt from the provisions of section 505 of such Act relating to new drugs because\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "subclause": [{"#tail": " \n", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 505(i) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, "#text": "it is intended solely for investigational use as described in "}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "#text": "\n                    ", "@id": "H626141A9732141AFB4F972C9B7320FAD", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application."}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "#text": "\n                    ", "@id": "H336FF325EC564BB09684BE9A03857740", "@commented": "no"}], "#text": "\n                  ", "@id": "H480745FCF1CE4DD1BEC8AF37CD2CBCBD", "@commented": "no"}], "#text": "\n                ", "@id": "H9F40E51E625847DDB8C0DBEC8CE37F60", "@commented": "no"}], "@commented": "no"}], "#text": "\n            ", "@id": "H52AE9CA84114409DA6A4DD325E2222B2"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "HBAF16F3548AF4B8D85346EDCDC0CB39E"}, "#text": "\n        ", "@id": "H76C8DABA9CD74E46A6DD99A232B07B31"}, {"#tail": " \n", "text": {"#tail": "\n      ", "quote": [{"#tail": " before ", "#text": "305,"}, {"#tail": ".", "#text": "1002"}], "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended, in subsection (a)(1), by inserting ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1010 of the Controlled Substances Import and Export Act", "@value": "Controlled Substances Import and Export Act/s:1010"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 960", "@value": "usc/21/960"}, "@parsable-cite": "usc/21/960", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Clarification to Import and Export statute"}, "#text": "\n        ", "@id": "HDAEDD3F74BCB41C28ACD3FB30C5CF7F6"}, {"#tail": "\n    ", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 402 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:402"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 842", "@value": "usc/21/842"}, "@parsable-cite": "usc/21/842", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Civil penalties"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "in subsection (a)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "H21FC41F7A1D144A7BDEC4F37B6CB75C4", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "quote": {"#tail": " at the end;", "#text": "or"}, "#text": "in paragraph (14), by striking "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H58242EC4047C4578921004BA6ABB5868", "#text": "\n            "}, {"#tail": " \n", "text": {"#tail": "\n          ", "quote": {"#tail": "; and ", "#text": "; or"}, "#text": "in paragraph (15), by striking the period at the end and inserting "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HA97C8240691845BC846BDB582727CF41", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "#text": "by inserting, after paragraph (15), the following:"}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "paragraph": {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (e) of section 825 of this title", "@value": "Controlled Substances Act/s:825/ss:e"}, "#text": "to violate ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(16)"}, "@id": "H8804113A357E447FA811F300D7582303", "#text": "\n                "}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "H4E1383445DF84915957CBB6DAFBC9B6D"}, "#text": "\n            ", "@id": "H885FA92357764E209A05C727E46737E8"}]}, {"#tail": "\n      ", "text": {"#tail": " \n", "#text": "in subsection (c)(1)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "H2BB0A17252A94CA289550DFA512C49B5", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "quote": [{"#tail": " the following: ", "#text": "subparagraph (B)"}, {"#tail": "; and", "#text": ", (C), or (D)"}], "#text": "by inserting, in subparagraph (A), after ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H887D3A3120A74D8DA084EE5CE4EC42B9", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "#text": "by inserting after subparagraph (B) the following: "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "."}, "#tail": "\n          ", "@id": "H972FCE4C74364F24B0E33E96A426902B", "@display-inline": "no-display-inline", "#text": " \n", "subparagraph": [{"@indent": "up2", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "#text": "\n                ", "@id": "H744FA6A7EA6F4607BFFBEC20BD26790D"}, {"@indent": "up2", "#tail": "\n              ", "text": {"#tail": "\n              ", "quote": {"#tail": " refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation. ", "#text": "at the retail level"}, "#text": "In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "#text": "\n                ", "@id": "H86D7930D57404418BA06D849C45A2FB6"}]}, "#text": "\n            ", "@id": "H489A4CF7ABCB40D5A9936B7C7677333B"}]}], "#text": "\n        ", "@id": "HE01AFE24958E472B9B2C70C71FA45B2F"}], "#text": "\n      ", "@id": "H0AA6E27EC6F44B89AA78F833C32F4046"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": " \n", "#text": "Identification and publication of list of products containing anabolic steroids"}, "subsection": [{"#tail": " \n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": "\u2019s discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this Act and the amendments made by this Act. The ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may publish in the Federal Register or on the website of the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " a list of products which the ", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}, {"#tail": " has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this Act and the amendments made by this Act.", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "#text": "\n        ", "@id": "H614AE6250F2F45D984BA6CA245F86455"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "The absence of a product from the list referred to in subsection (a) shall not constitute evidence that the product does not contain an anabolic steroid.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Absence from list"}, "#text": "\n        ", "@id": "H5E9D82B154E742048035597FC581466B"}], "#text": "\n      ", "@id": "HB64016946EA74F1E9AC51F21D1DC944A"}], "#text": " \n", "@id": "H550032FEDE93424A83A73D320B86FB01"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": " HR 4771 ENR: Designer Anabolic Steroid Control Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}